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Abstract
Introduction: Modern combined antiretroviral therapies (cART) allow to effectively suppress HIV-1 viral load, with the 90%
virologic success rate, meeting the WHO target in most clinical settings. The aim of this study was to analyse antiretroviral
treatment efficacy in Poland and to identify variables associated with virologic suppression.
Methods: Cross-sectional data on 5152 (56.92% of the countrywide treated at the time-point of analysis) patients on cART for
more than six months with at least one HIV-RNA measurement in 2016 were collected from 14 Polish centres. Patients’
characteristics and treatment type-based outcomes were analysed for the virologic suppression thresholds of <50 and <200
HIV-RNA copies/ml. CART was categorized into two nucleos(t)ide (2NRTI) plus non-nucleoside reverse transcriptase (NNRTI)
inhibitors, 2NRTI plus protease (PI) inhibitor, 2NRTI plus integrase (InI) inhibitor, nucleos(t)ide sparing PI/r+InI and three drug class
regimens. For statistics Chi-square and U-Mann Whitney tests and adjusted multivariate logistic regression models were used.
Results: Virologic suppression rates of <50 copies/mL were observed in 4672 (90.68%) and <200 copies/mL in 4934 (95.77%)
individuals. In univariate analyses, for the suppression threshold <50 copies/mL higher efficacy was noted for 2NRTI+NNRTI-
based combinations (94.73%) compared to 2NRTI+PI (89.93%), 2NRTI+InI (90.61%), nucleos(t)ide sparing PI/r+InI (82.02%)
and three drug class regimens (74.49%) (p < 0.0001), with less pronounced but significant differences for the threshold of
200 copies/mL [2NRTI+NNRTI-97.61%, 2NRTI+PI-95.27%, 2NRTI+InI-96.61%, PI/r+InI- 95.51% and 86.22% for three drug class
cART) (p < 0.0001). However, in multivariate model, virologic efficacy for viral load <50 copies/mL was similar across
treatment groups with significant influence by history of AIDS [OR:1.48 (95%CI:1.01–2.17) if AIDS diagnosed, p = 0.046],
viral load < 5 log copies/mL at care entry [OR:1.47 (95%CI:1.08–2.01), p = 0.016], baseline lymphocyte CD4 count ≥200 cells/
µL [OR:1.72 (95%CI:1.04–2.78), p = 0.034] and negative HCV serology [OR:1.97 (95%CI:1.29–2.94), p = 0.002]. For viral load
threshold <200 copies/mL higher likelihood of virologic success was only associated with baseline lymphocyte CD4 count
≥200 cells/µL [OR:2.08 (95%CI:1.01–4.35), p = 0.049] and negative HCV status [OR:2.84 (95%CI:1.52–5.26), p = 0.001].
Conclusions: Proportion of virologically suppressed patients is in line with WHO treatment target confirming successful
application of antiretroviral treatment strategy in Poland. Virological suppression rates depend on baseline patient char-
acteristics, which should guide individualized antiretroviral tre0atment decisions.
Keywords: antiretroviral treatment; virologic suppression; cART efficacy; WHO target; viral replication; virologic control
To access the supplementary material to this article please see Supplementary Files under Article Tools online.
Received 23 January 2017; Accepted 3 July 2017; Published 17 July 2017
Copyright: © 2017 Parczewski M et al. licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons
Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Introduction
Antiretroviral treatment leading to virologic suppression is
considered not only the most effective treatment option to
preserve immune system function but also to decrease the
risk of HIV- and non-HIV-associated co-morbidities and
death [1–3]. Controlling the HIV replication reduces the
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risk of HIV transmission and halts the spread of epidemics,
as well as limits evolution of the drug resistance, preserving
therapeutic options [1,4–7]. The initiation of antiretroviral
treatment in all patients with HIV infection, regardless of
lymphocyte CD4 count, is recommended by all major treat-
ment guidelines worldwide [8–10].
In Poland, approximately 0.1% of population is infected with
HIV with >21,000 diagnosed cases as of January 2017.
Approximately ten years ago, the dominant route of transmis-
sion shifted from intravenous drug use, with high number HCV
coinfections, to men who have sex with men (MSM) with
continuous expansion of epidemics in this group [11–13].
Despite the decreasing number of persons who injects drugs
intravenously, the increasing number of people combining sex
with illicit party drugs – chemsex (especially among MSM from
large cities, similar to the previously reported in other European
cities [14]), may fuel the HIV epidemics. Antiretroviral medica-
tions have been available since 1996, with Polish national HIV/
AIDS treatment and prevention programme stably funded since
this year. It is currently providing unrestricted and free coverage
of all EU antiretroviral registered medications and combina-
tions, as well as genotypic drug resistance, HIV viral load and
lymphocyte CD4 assays. Medical and psychological support of
HIV-infected people is provided by infectious diseases specia-
lists and specialist teams and is based on the annually updated
national treatment guidelines [15].
Modern combined antiretroviral therapies (cART) allow
to effectively suppress HIV-1 viral replication in majority
of treated cases, with the WHO target of 90% viral
suppression among people on antiretroviral therapy to
be reached by 2020 [16]. To meet the target, concerted
implementation of clinical care with optimized antiretro-
viral combinations and viral load monitoring is necessary.
The aim of this study was to analyse the current real-life
treatment efficacy in Poland and to identify variables
associated with virologic success.
Materials and methods
Study group and inclusion criteria
Cross-sectional data on the antiretroviral treatment efficacy
were collected for 5152 patients [(56.92% of total country-
wide treated cases (9052 patients) as for 30 June 2016 (data
on the number of cases on cART provided by Polish National
AIDS Centre, extracted from the national treatment database
on this date, and available on request at aids@aids.gov.pl)]
followed up in 14/17 Polish HIV treatment centres. The fol-
lowing treatment centres participated in the study (alphabe-
tical order): Białystok (n = 259, 5.03% of the study sample),
Bydgoszcz (n = 344, 6.68%), Chorzów (n = 808, 15.68%),
Gdańsk (n = 476, 9.24%), Kraków (n = 399, 7.74%), Lublin
(n = 74, 1.44%), Łódź (n = 320, 6.21%), Opole (n = 24,
0.46%), Ostróda (n = 41, 0.79%), Szczecin (n = 377, 7.32%),
Wrocław (n = 303, 5.88%), Warsaw [two centres: Hospital for
Infectious Diseases (n = 1522, 29.54%) and Medical University
(n = 124, 2.41%)], Zielona Gora (n = 81, 1.57%).
Study protocol was approved by the institutional review
board named Bioethical Committee of Pomeranian Medical
University in Szczecin, Poland (approval number KB-0012/
08/12). Research was conducted in accordance with the
Declaration of Helsinki. Data for all patients were anon-
ymized. As the patient data were coded and anonymous,
and there were no additional procedures associated with
this study, no separate written consent was obtained but
physicians informed subjects on the planned research and
checked for verbal non-opposition from their patients.
Study included participants on stable (uninterrupted)
cART, treated for at least six months, with at least one
HIV-RNA viral load measurement in 2016. Furthermore,
virologic measurement must have been performed after
at least six months of uninterrupted antiretroviral therapy.
The virological success was defined as HIV-1 viral load
either <50 RNA copies/mL or <200 RNA copies/mL with
outcomes analysed for these two HIV-RNA thresholds,
based on the measurement taken in 2016. The following
data were collected: age at HIV diagnosis, gender, date of
HIV diagnosis, route of transmission, history of hepatitis C
co-infection based on anti-HCV serology (anti-HCV positive/
negative, regardless HCV-RNA or HCV treatment status –
these data were not collected), history of AIDS (documen-
ted in the medical records), baseline HIV viral load (at the
care entry), as well as baseline, nadir and the latest lym-
phocyte CD4 counts. Date of diagnosis was assumed as the
date of positive screening HIV test if later confirmed by
Western-blot, immunoblotting or positive serum HIV-RNA.
As seroconversion time point was often unavailable in the
source documentation, therefore data for acute HIV infec-
tions were not collected – date of infection was based on
the date of the first positive, confirmed HIV test. Baseline
lymphocyte CD4 counts and HIV-RNA are defined as the
first documented result after diagnosis of HIV. The latest
lymphocyte CD4 count was taken as the last recorded value
in the medical records. Transmission route was self-defined
by the patient. For final analysis the haemophiliac and
vertically infected patients were excluded from the route
analyses due to the small sample sizes (15 cases of vertical
transmission and four with haemophilia).
Collected cART data included drug classes for the current
(last) treatment and their combinations [nucleos(t)ide (NRTI)
and non-nucleoside reverse transcriptase (NNRTI), protease
(PI), integrase (InI), CCR5 and fusion inhibitors]. Data on the
antiretroviral treatment history were not collected. For the final
analyses the following treatment groups were used: 2NRTI
+NNRTI, 2NRTI+PI, 2NRTI+InI, nucleos(t)ide sparing PI/r+InI as
well as combined category for all patients treated with three
drug class regimens. All data were extracted from the patient
files.
Statistical analyses
Statistical comparisons were performed using the Chi-
square tests for categorical variables. As all continuous
variables were distributed in the non-linear manner
U-Mann Whitney test was used for analyses.
Computations were performed with Statistica 12.0 PL soft-
ware (Statasoft, Poland). HIV viral load at baseline, lympho-
cyte CD4 count and age were analysed both as continuous
variables and as predefined categories. HIV-1 viral load was
categorized using a threshold of 5 log copies/mL, baseline
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and nadir lymphocyte CD4 count with a threshold of 200
cells/µL and last lymphocyte CD4 count of 500 cells/µL.
Additionally, age at diagnosis was subdivided into six cate-
gories (≤20 years, 21–30, 31–40, 41–50, 51–60 and
>60 years of age) similarly to the classification of age
categories for European cohorts [17]. To verify variables
associated with virologic success multivariate logistic
regression model was adjusted for AIDS history, lymphocyte
CD4 baseline and nadir <200 cells/µL, last lymphocyte CD4
count <500 cells/µL, HIV viral load at baseline <5 log copies/
mL and HIV transmission route.
Results
Current antiretroviral treatment combinations
In the analysed data set the most commonly used regimen
combined 2NRTI and one PI (n = 2285, 44.35%) cases, followed
by 2NRTI plus NNRTI (n = 1423, 27.62%) and 2NRTI plus inte-
grase inhibitor (InI) (n = 1054, 20.46%). NRTI sparing regimen of
PI/r+InI was used in 89 (1.73%) patients, while other combina-
tions in 301 (5.84%) individuals (Figure 1). Of the other combi-
nations the most common were three drug combinations of
NRTI+PI/r+InI (n = 80, 1.55%), NRTI+PI/r+NRTI (n = 72, 1.40%)
and protease inhibitor monotherapy (n = 35, 0.68%) (supple-
mental Figure 1). As at the time of data collection 196 (3.8%)
patients received three drug regimens a separate cumulative
category was created for them and added to the statistical
analyses.
Antiretroviral treatment efficacy
Undetectable viral load (<50 copies/mL) was observed in
4672 (90.68%) individuals. Furthermore, among 262
(5.09%) antiretroviral treated patients last HIV-1 viral load
was in the range of 50–200 copies/mL indicating 95.77%
overall treatment efficacy if threshold <200 copies/mL was
adopted (Table 1). At the time of treatment efficacy analy-
sis the majority of individuals presented with lymphocyte
CD4 count >500 cells/µL (n = 3103, 60.23%). Last lympho-
cyte CD4 count in the range of 200–499 copies was noted
in 1778 (34.51%) cases, and <200 cells/µL among 271
(5.26%) patients. Notably, antiretroviral treatment efficacy
was significantly higher, for both HIV-RNA thresholds (<50
copies/mL and <200 copies/mL) for MSM, patients with no
history of AIDS, anti-HCV negative, cases with higher lym-
phocyte CD4 counts at care entry, nadir and last analysis as
well as for individuals with lower baseline viral load.
Additionally, for the threshold <200 copies/mL male gender
was associated with higher virologic success rate (presented
in detail in the Table 1).
Treatment efficacy by age
For 3023 patients with available data on the age at diagnosis,
6.75% (n = 204) were ≤20 years of age. For themajority of cases
HIV diagnosis was established between 21 and 30 (n = 1170,
38.7%) and 31–40 (n = 1030, 34.07%) years of age. Diagnoses at
ages between 41–50 years were noted among 414 cases
(13.7%), while between 51–60 among 155 (5.13%) patients
and >60 years among 50 (1.65%) of individuals.
Treatment success rates for the threshold of 50 HIV-RNA
copies/mL were similar across all age categories (≤20 years
at diagnosis: 87.75%, 21–30 years: 89.74%, 31–40 years:
91.07%, 41–50 years: 88.65%, 51–60 years: 90.97% and
>60 years: 88.0%, p = 0.28). Applying the <200 copies/mL
virologic efficacy threshold, higher rate of treatment failure
was observed for patients aged ≤20 years at diagnosis
(93.14% with viremia <200 copies/mL) compared to other
age categories (21–30 years: 95.47%, 31–40 years: 97.09%,
41–50 years: 96.38%, 51–60 years: 96.13% and >60 years:
100 %, p = 0.023). For <200 copies/mL threshold, median age
at diagnosis was also notably lower [median: 28 (IQR:23–36)]
among virologically failing patients compared to the sup-
pressed ones [median: 32 (IQR: 26–39)], p = 0.007.
Treatment efficacy by the antiretroviral regimen type
For the <50 copies/mL threshold notable differences across
regimen types were observed. For this threshold signifi-
cantly higher virologic success rate was noted for 2NRTI
+NNRTI-based combinations (94.73%) compared to 2NRTI
+PI (89.93%), 2NRTI+InI (90.61%), nucleos(t)ide sparing PI/r
+InI (82.02%) and three drug class regimens (74.49%)
(Figure 2(a)). However, for <200 copies/mL threshold, treat-
ment efficacies were similar, with the following virologic
success rates: 2NRTI+NNRTI – 97.61%, 2NRTI+PI − 95.27%,
2NRTI+InI – 96.61% and 95.51% for nucleos(t)ide sparing
PI/r+InI combinations. Suppression rates <200 copies/mL
were consistently and significantly lower for the three
drug class regimens (86.22%) (Figure 2(b)). Antiretroviral
treatment efficacy for the threshold of 50 copies/mL was
notably lower for NRTI sparing PI/r+InI combinations com-
pared to combinations containing two NRTI with either PI,
InI or NNRTI (p < 0.0001). This difference was less pro-
nounced for the threshold of 200 copies/mL (p = 0.0036)
(not presented in Figure 2).
Treatment efficacy by patient characteristics
Significant differences in the demographic, clinical, immu-
nologic as well as virologic characteristics were observed
for the five analysed treatment combinations (2NRTI plus
Figure 1. Main antiretroviral regimens used at the time of the
last viral load measurement in the analysed data set.
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Table 1. Virologic outcomes of the antiretroviral treatment in the entire cohort using the HIV-1 viral load thresholds of 50 copies/mL and 200 copies/mL associated with clinical,
epidemiological and virologic variables.
Last viral load
<50 copies/mL
Last viral load >
50 copies/mL p-value
Last viral load
<200 copies/mL
Last viral load >
200 copies/mL p-value Total
Gender, n (%)
Female 872 (89.25) 105 (10.75) 0.087 913 (93.45) 64 (6.55) <0.0001 977 (18.96)
Male 3800 (91.02) 375 (8.98) 4021 (96.31) 154 (3.69) 4175 (81.04)
History of AIDS-defining condition (%)
Yes (AIDS) 1083 (86.23) 173 (13.77) <0.0001 1175 (93.55) 81 (6.45) <0.0001 1256 (25.37)
No (non-AIDS) 3413 (92.4) 281 (7.6) 3566 (96.51) 129 (3.49 3695 (74.63)
Dominant transmission route, n (%)a
IDU 1085 (86.52) 169 (13.48) <0.0001 a 1166 (92.98) 88 (7.02) <0.0001a 1254 (26.11)
MSM 2277 (93.24) 165 (6.76) 2383 (97.58) 59 (2.42) 2242 (50.84)
HET 985 (90.53) 103 (9.47) 1034 (95.04) 54 (4.96) 1088 (22.65)
VER 13 (86.67) 2 (13.33) 14 (93.33) 1 (6.67) 15 (0.31)
HEM 4 (100) 0 4 (100) 0 4 (0.08)
Age at diagnosis, median years (IQR) 32 (26–39) 31 (25–38) 0.45 32 (26–39) 28 (23–36) 0.007 32 (26–39)
Age at treatment initiation, median years
(IQR)
35 (29–40) 34 (28–40) 0.73 34 (29–41) 33 (26–38) 0.068 35 (28–40)
Years on treatment, mean (SD) 5.8 (4.54) 6.32 (4.83) 0.1 5.83 (4.55) 6.64 (4.81) 0.026 5.87 (4.57)
HCV coinfection status at data collection, n (%)
Anti-HCV positive 1318 (86.65) 203 (13.35) <0.0001 1418 (93.23) 103 (6.77) <0.0001 1521 (39.43)
Anti-HCV negative 2158 (92.38) 178 (7.62) 2271 (97.22) 65 (2.78) 2336 (60.57)
Last lymphocyte CD4 cell counts, median (IQR)
cells/µl
558 (398–740) 517 (299–692) <0.0001 584 (395–742) 455 (258–629) <0.0001 552 (389–735)
Last lymphocyte CD4 cell counts <500 cells/µL
Yes 1819 (88.78) 230 (11.22) 0.0001 1930 (94.19) 119 (5.81) <0.0001 2049 (39.77)
No 2853 (91.94) 250 (8.06) 3004 (96.81) 99 (3.19) 3103 (60.23)
Lymphocyte CD4 cell counts at baseline,
median (IQR) cells/µL
321 (162–487) 243 (87–459) <0.0001 318 (157–485) 278 (116–459) 0.04 317 (155–485)
Baseline lymphocyte CD4 cell counts <200 cells/µL, n (%)
Yes 1229 (87.79) 171 (12.21) <0.0001 1333 (95.21) 67 (4.79) 0.036 1400 (31.48)
No 2817 (92.45) 230 (7.55) 2941 (96.52) 106 (3.48) 3047 (68.52)
Nadir lymphocyte CD4 cell counts, median
(IQR) cells/µL
239 (117–350) 204 (67–296) <0.0001 234 (111–349) 160 (68–296) <0.0001 248 (109–347)
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either PI, NNRTI or InI, nucleoside sparing PI/r+InI combina-
tions and three drug regimens) when compared separately
(see Table 2 for detailed group size, percentage and statis-
tical data).
Treatment with nucleos(t)ide plus non-nucleoside reverse
transcriptase inhibitors was associated with the most favour-
able clinical, immunological and virologic characteristics com-
pared to other analysed antiretroviral combinations: the least
common history of AIDS, the highest baseline, nadir and last
lymphocyte CD4 counts, as well as the lowest baseline HIV-1
viral load (supplemental figure 2 a,b,c). Distribution of transmis-
sion routes was similar for 2NRTI+NNRTI- and 2NRTI+InI-based
treatments.
Among 2NRTI+PI-treated patients AIDS history was notably
more common while baseline and nadir lymphocyte CD4
counts were lower compared to 2NRTI+InI, with similar last
lymphocyte CD4 count and baseline HIV-1 viral loads. Also the
percentage of 2NRTI+PI-treated female as well as anti-HCV-
positive individuals was significantly higher compared to
2NRTI+NNRTI and 2NRTI+InI. Age at HIV diagnosis and anti-
retroviral treatment initiation was similar for all three (2NRTI
+PI, 2NRTI+NNRTI, 2NRTI+InI) most common regimens.
Nucleos(t)ide-sparing PI/r+InI combinations were com-
monly used among patients with history of AIDS as well
as injection drug use, both with similar frequency to 2NRTI
+PI-based regimens. These patients were notably older at
HIV diagnosis compared to any other combination (except
for the similar age of the therapy initiation for patients on
triple class therapy) and presented with the highest base-
line HIV-1 viral loads. Despite the fact that baseline and
nadir lymphocyte CD4 count was lower for nucleos(t)ide-
sparing PI/r+InI regimens compared to 2NRTI+NNRTI or
2NRTI+InI the last lymphocyte CD4 count was similar to
any nucleos(t)ide-based combinations.
It should also be observed that in the group treated with
three drug class combinations, the highest percentage of
women, individuals with history of AIDS or injection drug
use and anti-HCV-positive cases was noted. Also median base-
line, nadir and last lymphocyte CD4 count were the lowest in
this group compared to any other treatment combination.
This group also commonly presented with high viral load,
comparable only to the group on nucleoside sparing regi-
mens, with viral load >5 log copies/mL observed in 57.62%
of cases and 63.51% for both combinations, respectively.
Lastly, differences for the number of years on antiretroviral
treatment were notable across all analysed categories, except
between nucleoside sparing PI/r+InI and three drug class regi-
mens. As expected, the shortest time was noted for nucleos(t)
ide plus integrase inhibitor [median: 2 (IQR:1–6) years] combi-
nations followed by nucleos(t)ide plus non-nucleoside reverse
transcriptase inhibitors [median: 4 (2–8) years], nucleos(t)ide
plus protease inhibitors [median: 5 (3–8) years], nucleos(t)ide
sparing PI/r+InI [median: 7 (4–12) years] and finally, three drug
class treatments [median: 9.5 (6–13) years].
Variables associated with treatment success in the
multivariate model
In multivariate model, adjusted for AIDS history, lymphocyte
CD4 baseline and nadir <200 cells/µL, last lymphocyteT
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Figure 2. (a) Virologic success rates (<50 copies/mL) by the last ARV combination. (b) Virologic success rates (<200 copies/mL) by the last
ARV combination. For statistics Chi-square test was used.
Parczewski M et al. Journal of the International AIDS Society 2017, 20:21847
http://www.jiasociety.org/index.php/jias/article/view/21847 | http://dx.doi.org/10.7448/IAS.20.1.21847
6
Table 2. Differences in patient characteristics underlying last treatment option
2NRTI+PI
2NRTI
+NNRTI 2NRTI+InI
PI+InI,
nucleos(t)
ide
sparing
Three drug
class
treatments
P*
2NRTI
+PI vs.
2NRTI
+NNRTI
P*
2NRTI
+PI vs.
2NRTI
+InI
P*
2NRTI
+PI vs.
PI+InI
P*
2NRTI
+PI vs.
3 drug
P*
2NRTI
+NNRTI
vs.
2NRTI
+InI
P*
2NRTI
+NNRTI
vs. Pi
+InI
P*
2NRTI
+NNRTI
vs. 3
drug
P*
2NRTI
+InI vs
PI+InI
P*
2NRTI
+InI vs
3 drug
P*
PI+InI
vs 3
drug
Gender, n (%)
Female 475 (20.79) 223 (15.67) 174 (16.51) 18 (20.22) 59 (30.1) 0.0001 0.003 0.89 0.002 0.57 0.25 <0.0001 0.36 <0.0001 0.08
Male 1810 (79.21) 1200 (84.33) 880 (83.49) 71 (79.78) 137 (69.9)
History of AIDS-defining condition (%)
Yes (AIDS) 648 (29.29) 237 (17.36) 218 (21.82) 25 (29.41) 100 (52.63) <0.0001 <0.0001 0.98 <0.0001 0.007 0.005 <0.0001 0.1 <0.0001 0.0004
No (non-AIDS) 1564 (70.71) 1128 (82.64) 781 (78.18) 60 (70.59) 90 (47.37)
Dominant transmission route, n (%)
IDU 676 (31.63) 252 (18.99) 180 (18.26) 26 (32.5) 85 (48.3) <0.0001 <0.0001 0.77 <0.0001 0.83 0.013 <0.0001 0.042 <0.0001 0.005
MSM 956 (44.74) 784 (59.08) 584 (59.23) 38 (47.5) 47 (26.7)
HET 499 (23.35) 283 (21.33) 219 (22.21) 16 (20.0) 42 (23.86)
VER 2 (0.09) 0 2 (0.2) 0 1 (0.57)
HEM 4 (0.19) 8 (0.6) 1 (0.1) 0 1 (0.57)
Age at diagnosis, median years (IQR) 31 (25–38) 31 (26–38) 32 (25–38) 38 (29–46) 33 (27–40) 0.59 0.33 <0.0001 0.065 0.63 <0.0001 <0.0001 0.0001 0.17 0.014
Age at treatment initiation, median
years (IQR)
34 (29–40) 28 (28–40) 33 (28–40) 38 (29–46) 36 (30–42) 0.49 0.83 0.001 0.016 0.69 0.0007 0.1 0.002 0.02 0.22
Years on treatment, median (IQR) 5 (3–8) 4 (2–8) 2 (1–6) 7 (4–12) 9.5 (6–13) <0.0001 <0.0001 0.0001 <0.0001 <0.0001 <0.0001 0.008 <0.0001 <0.0001 0.066
HCV coinfection status at data collection, n (%)
Anti-HCV positive 794 (50.8) 311 (27.82) 254 (30.02) 26 (34.67) 92 (56.1) <0.0001 <0.0001 0.006 0.19 0.28 0.20 <0.0001 0.4 <0.0001 0.002
Anti-HCV negative 769 (49.2) 807 (72.18) 592 (69.98) 49 (65.33) 72 (43.9)
Last lymphocyte CD4 cell counts <500 cells/µL
Yes 950 (41.58) 494 (34.72) 427 (40.51) 37 (41.57) 99 (50.51) <0.0001 0.56 0.99 0.015 0.003 0.18 <0.0001 0.84 0.009 0.16
No 1335 (58.42) 929 (65.28) 627 (59.49) 52 (58.43) 97 (49.49)
Baseline lymphocyte CD4 cell counts <200 cells/µL, n (%)
Yes 723 (35.53) 241 (20.55) 281 (31.02) 41 (28.24) 86 (50) <0.0001 0.017 0.017 0.0002 <0.0001 <0.0001 <0.0001 0.001 <0.0001 0.7
No 1312 (64.47) 923 (79.45) 625 (68.98) 44 (51.76) 86 (50)
Nadir lymphocyte CD4 cell counts <200 cells/µL, n (%)
Yes 1043 (50.80) 312 (26.74) 349 (38.69) 50 (58.82) 123 (70.69) <0.0001 <0.0001 0.14 <0.0001 <0.0001 <0.0001 <0.0001 0.0003 <0.0001 0.06
No 1010 (49.20) 855 (73.26) 553 (61.31) 35 (41.18) 51 (29.31)
HIV viral load at baseline > 5 log copies/mL, n (%)
Yes 723 (41.7) 268 (26.56) 323 (40.99) 47 (63.51) 87 (57.62) <0.0001 0.74 0.0002 0.0002 <0.0001 <0.0001 <0.0001 0.0002 0.0002 0.39
No 1011 (58.3) 741 (73.44) 465 (59.01) 27 (36.49) 64 (42.38)
*p-values calculated for the comparisons between selected regimen combinations.
IDU, intravenous drug use; MSM, men having sex with men; HET, heterosexual; VER, vertical; HEM, haemophiliac, IQR, interquartile range.
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CD4 < 500 cells/µL, HIV viral load at baseline <5 log copies/mL
and transmission route, virologic treatment efficacy, expressed
as HIV-1 viral load <50 copies/mL proved similar across the
analysed treatment groups (Figure 3). Baseline characteristics
significantly influenced the probability of treatment success
(defined as HIV-1 viral load <50 copies/mL) with lack of history
of AIDS, baseline viral load < 5 log copies/mL, baseline lym-
phocyte CD4 count ≥200 cells/µL and negative anti-HCV asso-
ciated with notably better virologic outcomes. For the
threshold <200 copies/mL higher likelihood of virologic success
was only associated with baseline lymphocyte CD4 count ≥200
cells/µL, and negative anti-HCV serology (Figure 3).
Discussion
This study presents national data on antiretroviral treat-
ment efficacy for the majority of patients in care in
Poland and represents the largest data set published so
far, based on 56.92% of all countrywide treated patients
for the time of analysis. The highest proportion of cases
received nucleos(t)ide backbone treatment combined with
PIs, followed by combinations containing NNRTI and InI.
These results are similar to other European cohorts
[18,19]. Previous published Polish data were limited to
single-centre cohort observed until February 2013 and indi-
cated higher frequency (72.4%) of protease inhibitor use
with similar percentage of NNRTI used (26.1%) and infre-
quent treatment with integrase inhibitors (<1.5%) [20].
Integrase inhibitors were introduced in Poland in 2008
with raltegravir, elvitegravir containing regimens in 2012
and dolutegravir in 2014. Our current data reflect the
trend for increased use of integrase inhibitors and switch-
ing-off from protease inhibitors as indicated by the most
recent treatment guidelines [9,15]. Implementation of inte-
grase inhibitors was previously associated with good
virologic efficacy, as well as improved treatment safety
and tolerability and low risk of transmission of drug resis-
tance [21–23], therefore further increase in the use of this
class may be expected in the future.
Antiretroviral treatment efficacy exceeded 90% and 95%
for the thresholds of 50 and 200 HIV-RNA copies/mL,
respectively. Observed differences in the ratio of virologic
success were largely dependent on the baseline patient
characteristics and less favourable clinical, immunologic
and virologic profile reflected by increased odds ratios of
failures associated with the history of AIDS, lower baseline
lymphocyte CD4 count, higher HIV viral load at care entry
or hepatitis C coinfection and is likely associated with
delayed linkage to care. Virologic suppression rates >90%
are consistent with the WHO 90–90–90 target and similar
to the ones observed for European high income countries
such as UK (94% for the threshold of 200 copies/mL) [24],
Sweden (94.7% with viral load <50 copies/mL and 98.5%
<200 copies/mL) [25], Netherlands (94.2–96.6% for the
threshold of 100 copies/mL depending on the number of
years on treatment) [26] or ~95% for Switzerland (<200
copies/mL) [27] and were higher compared to some coun-
tries such as Georgia (85%) or Japan (87.7%) [28,29].
Presented virologic outcomes indicate high efficacy of the
current, free healthcare and antiretroviral treatment access
for all Polish citizens and residents. Similar system and
outcomes were presented for France, with the virologic
success rates of 90.3% (threshold <500 copies/mL, the
years 2009–2011) in a large (>80,000 people) data set [19].
In our study virologic efficacy for the threshold of <200
copies/mL was lower for patients aged ≤20 years at diag-
nosis. Similarly in the Cohere study group, virological suc-
cess rates were notably lower among individuals aged
≤20 years at diagnosis, which is likely related to adherence
issues among adolescents and young adults or may reflect
Figure 3. Multivariate logistic regression model presenting factors associated with virologic success for the threshold of 50 (red) and 200
(blue) HIV-RNA copies/mL. Odds ratios, 95% confidence intervals as well as p-values are presented on the right.
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underlying psychological, social, addiction or mental pro-
blems in this group [17,30]. In the light of the lifelong
antiretroviral treatment this age group requires special
clinical focus and treatment optimization to prevent the
development of drug resistance and avoid disease progres-
sion [31]. Rate of antiretroviral treatment success presented
in this study should also be related to the other levels of HIV
care cascade in Poland – namely percentage HIV diagnosed
and on antiretroviral treatment. Significant gaps exist in this
knowledge for the country. Firstly, number of undiagnosed
individuals is estimated at ~43% for overall population; how-
ever in the recent model, percentage undiagnosed MSMwas
predicted to reach 69.3% (with 53.9–76.1 confidence inter-
val) [32,33]. Low testing rates were related to existence of
barriers to testing among key populations such as MSM and
IDUs with large proportion of data on the probable transmis-
sion being underreported [34,35]. Also, European Centre for
Disease Prevention and Control (ECDC) data estimate that
only 63% of people diagnosed received cART as of
2015–2016; however, this number may be underestimated
as the number of HIV-infected patients living and receiving
treatment in European Union is unknown. Sample presented
in the current study may miss the populations with infre-
quent or irregular follow-up, diagnosed but unlinked to care
and most recently diagnosed patients with cART adminis-
tered for less than six months.
It should be noted that our data revealed notable differ-
ences in the frequency of viral suppression rates related to
the last antiretroviral treatment option using univariate
statistics, mitigated in the multivariate models by the initial
clinical (history of AIDS), virologic (HIV-1 viral load at care
entry of 5 log copies/mL) and immunologic (baseline lym-
phocyte CD4 count of 200 cells/µL) patient characteristics
and the status of HCV coinfection. Some of the treatment
efficacy differences reflect selection of patients with more
favourable profile – which is clearly the case of the 2NRTI
+NNRTI-based regimens. This group presented with the
lowest median HIV-1 viral load, the highest baseline and
nadir lymphocyte counts and the least frequent history of
AIDS – variables known to affect treatment efficacy [36–
38]. Also, as our cross-sectional analysis evaluated only last
treatment option, patients with prior virologic failure were
likely switched to other combinations, therefore the NNRTI-
treated group most likely included stably treated, well-
adherent patients. On the other hand, of the most com-
monly used combinations 2NRTI+PI-treated cases presented
with the least favourable clinical profile reflected by high
percentage of AIDS diagnoses and low baseline/nadir lym-
phocyte CD4 counts – comparable to nucleoside-sparing PI/
r+InI. Presented data were obtained for the real-life clinical
setting with the baseline patient characteristics and data
from clinical trials guiding therapeutic decisions may also
reflect lower virologic efficacy of boosted protease inhibitor
compared to 2NRTI + NNRTI combinations noted in clinical
trials [39]. Less favourable outcome related with 2NRTI+InI
use compared to 2NRTI+NNRTI may be associated with
shorter availability of this drug class and selection of
patients with lower lymphocyte CD4 counts and higher
HIV-1 viral load at care entry. Most likely, virologic efficacy
data from observational cohorts will reflect the favourable
outcomes noted in the randomized controlled trials as the
use of InI further increases among both antiretroviral treat-
ment naive and experienced patients [40–43].
Due to special clinical interest analysis included two
additional treatment groups: nucleoside-sparing PI/r+InI-
treated cases and three drug class treated individuals.
Switching off the nucleos(t)ide tends to be selected in
aging patients with increasing risk of NRTI-related adverse
events, especially kidney injury and loss of bone mineral
density [44]. Virological outcomes of dual PI/r+InI therapy
vary significantly, often with comparable efficacy to the
standard nucleos(t)ide-containing triple regimen. However,
they were proven to be less efficacious among patients
with lymphocyte CD4 nadir <200 copies/mL and HIV-1
viral loads >5 log copies/mL [45–47]. It was also associated
with emerging resistance and may limit the subsequent
therapeutic options [48,49]. NRTI-sparing PI/r+InI regimens
in our study was selected in older patients as reflected by
the higher age at HIV diagnosis and antiretroviral treatment
initiation in this subgroup, also the length of previous
therapy was the longest for these individuals. Notably, this
group presented with the highest baseline HIV-1 viral load –
a factor mentioned earlier associated with the decreased
virologic efficacy for the two-drug NRTI sparing regimens.
This might have resulted in the lower frequency of viral
load suppression to <50 copies/mL and underscores the
necessity for attentive implementation of dual therapy
among patients with viremia exceeding 5 log copies/mL.
Finally, combination of at least two active antiretroviral
compounds is required to achieve virologic control among
treatment-experienced cases. In the setting of treatment
failure and emerging drug resistance it may be necessary
to combine three or more classes of antiretroviral drugs
[19,50–52]. In this analysis we have included the three
drug class treated individuals who represent difficult-to-
treat cases with likely prior attempts of therapy optimiza-
tion. This was reflected by the longest time of antiretroviral
exposure (median 9.5 years) in this subgroup. The 86.22%
suppression rate for the threshold of 200 copies/mL, despite
being lower than for other options, seems satisfactory, espe-
cially in the light of high frequency of AIDS diagnosis, poor
immunologic characteristics, common history of injection
drug use and HCV coinfection in this group. It should be
emphasized that non-standard regimens presented and dis-
cussed earlier were used among more experienced patients
as reflected by age and length of follow-up, with possible
higher rate of drug resistance adversely influencing treat-
ment success rates [53]. Second-line treatment regimens
have been previously associated with decreased virologic
efficacy [38,54]. Additionally, some of the observed associa-
tions, especially for the NRTI-sparing and >3 drug regimens
may be related to the treatment sequencing in highly experi-
enced patients to optimize the treatment for previous resis-
tance or observed toxicity.
The study has the following limitations: Firstly, only the
individuals with viral load assessment performed within
the last six months from database closure were investi-
gated, which may have led to overestimation of the
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virological success rates based only on the patients who
remained in the close care. Some of early discontinua-
tions might have been missed by this criterion; however,
HIV viral loads are assessed every three to six months
and such a criterion best reflected clinical practice in
Poland. Secondly, for this study it was not possible to
assess the history of the antiretroviral regimen changes;
therefore, statistics was based on the last recorded anti-
retroviral treatment combination. This limitation is
related to the unavailability of electronic records reflect-
ing treatment changes. Both limitations are at least par-
tially mitigated by the group size which strengthens
validity of the presented results.
Conclusions
To sum up, presented data indicate high efficacy of the
antiretroviral treatment in Poland, fully in line with the mil-
lennium WHO 90% target and reflects success of comprehen-
sive HIV management in Poland. Differences in the
antiretroviral treatment efficacy are based on the patient
characteristics and reflect individualized treatment decisions
related to variety of clinical conditions such as infection
status, age or adherence. It should be noted, however, that
presented high frequency of virologic suppression does not
result in the decrease of the number of new cases – HIV
epidemics in Poland is expanding, especially among MSM
[32,35]. While there is a clinical success, further efforts should
focus on prevention, testing and linkage to care. Unrestricted
and free access to antiretroviral medications allow to main-
tain high percentage of virologically suppressed individuals.
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